Inimmune Named in Top 20 Innovative Immuno-Oncology Companies in the US
The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies.
Montana’s Inimmune recently made the top-20 list.
